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A hypothesis is formulated on viral interaction between HHV-6A and EBV as a pathogenic mechanism in Multiple
Sclerosis (MS). Evidence of molecular and genetic mechanisms suggests a link between HHV-6A infection and EBV
activation in the brain of MS patients leading to intrathecal B-cell transformation. Consequent T-cell immune
response against the EBV-infected cells is postulated as a pathogenic basis for inflammatory lesion formation in the
brain of susceptible individuals. A further link between HHV-6A and EBV involves their induction of expression of
the human endogenous retrovirus HERV-K18-encoded superantigen. Such virally induced T-cell responses might
secondarily also lead to local autoimmune phenomena. Finally, research recommendations are formulated for
substantiating the hypothesis on several levels: epidemiologically, genetically, and viral expression in the brain.
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Background
The role of viral interactions in pathogenesis has been
reported for several human diseases. Examples are coin-
fection with HCV and HIV [1] or other hepatitis viruses
[2] as well as with HIV and HHV-6 [3] or HHV-7 [4].
For a long time a viral aetiology of Multiple Sclerosis
(MS) has been suspected und discussed. Evidence for it
has often been circumstantial and sometimes not reprodu-
cible. However, in the past 20 to 30 years the importance
of two viruses for MS has stood the test of time and recent
reviews have summarized the evidence for their
aetiological role in MS – Human Herpes Virus 6A (HHV-
6A) [5] and Epstein Barr Virus (EBV) [6, 7]. The hypoth-
esis on a viral interaction between HHV-6A and EBV as a
pathogenic mechanism in multiple sclerosis (MS) has first
been formulated by the author in 2004 [8]. However, a
possible connection between the two herpes viruses has
not been further studied in detail so far. Here, it will be
argued that that the involvement of two different herpes
viruses in MS is not circumstantial but fundamental to the
aetio-pathogenetic processes in MS. This view could
partly explain why two highly prevalent viruses are caus-
ing a relatively rare disease. First, some of the pertinent
evidence for the involvement of the two viruses in MS will
be summarized, and then the pieces of the puzzles will be
put together in sight of new evidence supporting the
picture.
HHV-6A
An important fact is that all evidence relating MS to
HHV-6 involves HHV-6A but not HHV-6B, two quite
different herpes viruses [9]. Leibovitch & Jacobson
(2014) have recently reviewed the role of HHV-6A in
MS [5].
The basic concept is that HHV-6A is a neurotropic
virus infecting the astrocytes of MS-patients [10]. The
active replication of HHV-6A in MS patients correlates
with a polymorphism of MHC2TA (rs4774C) [11], a
gene that has been associated with MS [12]. MHC2TA is
coding for the MHC class II transactivator (CIITA)
which plays an essential role in the expression of MHC
class II molecules by astrocytes [13]. MHC class II
molecules are essential for presentation of antigens to
CD4-T-cells, although IFN-γ is needed as an additional
factor to enable astrocytes to do so [14, 15]. There seems
also to be a combined effect of IFN-γ and HHV-6A
infection on astrocytes resulting in the upregulation of
ICSBP (IRF8) in astrocytes [16], a gene that has been as-
sociated with MS [17]. The HHV-6A replication related
MHC2TA rs4774 minor allele (C) seems to diminish the
expression of MHC class II molecules and therefore
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might allow the immune escape of the virus, similarly as
described for CMV in an astrocytoma cell line [18].
Nevertheless, oligoclonal IgG from MS patients, specific
for the HHV-6-A major capsid proteins have been
demonstrated [19], indicating that viral immune escape is
not absolute.
EBV
The role of EBV in MS has recently been reviewed by
Pender (2011) [6] and Owens & Bennett (2012) [7]. Here,
the basic concept is that B-cells in the brain of MS-
patients are EBV-transformed, and that the cellular
immune response towards the EBV-infected cells is the
hallmark of the inflammatory basis of MS. Intrathecal
CD8 T-cells of MS patients recognizing lytic Epstein-Barr
virus proteins have been described recently [20, 21].
Indirect evidence for transformation of B-cells in the
CNS of MS patients comes from early observations that
the pattern of oligoclonal bands in the CSF of MS
patients is stable over time [22]. This patient-specific
antibody “fingerprint” has recently been analysed at the
level of epitope specificities that stayed identical over
several years [23]. A systemic examination of the speci-
ficities of such antibodies produced by B-cells in the
CNS of MS patients revealed no MS-specific pattern
[24]. One explanation for these findings would be that
such specificities are random as one would expect from
EBV-transformed and immortalized B-cells [25].
EBV persistence has been described in post-mortem
brain tissue of MS patients and viral reactivation has
been localized to acute lesions and ectopic B-cell follicles
in the meninges [26]. Notably, EBNA2+ and LMP1+
cells were detected in perivascular inflammatory cell
infiltrates in active white matter lesions. However, others
could not reproduce such direct evidence of EBV infection
in brains of MS patients and the issue still is controversial
(reviewed in [27]). On the other hand, oligoclonal IgG
from MS patients, specific for the EBV proteins BRRF2
and EBNA-1 could be demonstrated [28, 29].
The link
The basic concept is that HHV-6A actives latent EBV in
B-cells resident in MS lesions.
The activation of EBV in B-cells by HHV-6 has first
been reported 1993 by Louis Flamand et al [30]. In 1995
Laura Cuomo et al. [31] demonstrated that such activation
of EBV is only a property of HHV-6A but not HHV-6B.
Later Laura Cuomo et al. [32] have shown that HHV-6A
not only induces EBV-encoded proteins associated with
the lytic cycle but also upregulates expression of
EBV-encoded growth-transformation-associated pro-
teins, namely LMP1 and EBNA-2.
The activation of EBNA-2 expression by HHV-6A de-
serves a special interest since recently it has been found
that the association between EBV and MS is dependent
on genetic variants of EBV involving particularly the
EBNA2 gene, the most polymorphic region of the viral
genome [33].
This genetic link between EBNA2 polymorphism and
MS again deserves further interest since EBNA-2
directly interacts with the cellular DNA-binding protein
RBPJ-κ (recombination signal-binding protein J kappa), a
ubiquitous protein of the Notch signalling pathway that
plays an important role in Epstein-Barr virus infection.
Notch signalling may play a role in MS pathogenesis by
affecting function of both immune and glial cells
(reviewed in [34]).
EBNA-2 regulation of transcription through RBPJ-κ is
essential for resting B-lymphocyte conversion to immortal
B-cells [35, 36]. Interestingly, RBPJ is a possible autoanti-
gen in MS recognized by CSF-derived immunoglobulin G
in a subset of patients with MS [37]. On the molecular
level, therefore, the link between HHV-6A and EBV can
be pinned down to two interacting proteins: HHV-6A in-
duced EBNA-2 and cellular host protein RBPJ-κ. Such
physical interaction between a foreign (viral) protein and a
self-protein might well turn the RBPJ-κ into an autoanti-
gen, similarly as it is the case with gliadin and tissue trans-
glutaminase in celiac disease.
The upregulation of LMP1 by HHV-6A in EBV
infected cells [32] suggests a further interesting link to
MS: As shown in EBV-related nasopharyngeal carcinoma
cells, LMP1 induces an increasing expression of kappa
light chains [38]. On the other hand, as known for many
years, intrathecal expression of kappa light chains is a
consistent finding in CSF of MS patients, having even a
prognostic value [39]. A recent multicentre study has
confirmed the diagnostic value of kappa free light chains
in CSF as diagnostic biomarkers in MS [40]. The ques-
tion remains what cells in the CNS would produce the
kappa light chains. Apart from B-cells, interesting candi-
dates are astrocytes infected with both EBV [41] and
HHV-6A [10]. EBV infection of astrocytes activates the
HERV-W/MSRV/syncytin-1 [41]. The HERV-W-related
retroelement, MS retrovirus (MSRV), particularly its en-
velope protein syncytin-1, has been reported to be over-
expressed in white matter lesions of individuals with MS
(reviewed in [42]).
A further link between HHV-6A and EBV comes from
the observation that both viruses induce expression of
the human endogenous retrovirus HERV-K18-encoded
superantigen [43, 44]. Furthermore, the HERV-K18.3
env genotype is a potential risk factor for MS [45].
Interestingly, the HERV-K18-encoded superantigen
stimulates T-cells carrying receptors of the Vβ13
family [46] in which also T-cell clones with specificity
for an immunodominant peptide of myelin basic
protein (MBP) have been found in MS patients [47].
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This example is demonstrating how a viral infection
might lead to or enhance an autoimmune reaction.
Disease-modifying therapies in MS
Support for a combined pathogenic role of HHV-6A and
EBV in MS might come from studies involving disease-
modifying therapies. In fact, the first trial in MS with
specific anti-herpes virus treatment showed that acyclo-
vir might inhibit the triggering of MS [48]. Later, the
introduction of IFN-β as the first disease modifying
therapy of MS was initially based on the assumption that
the anti-viral effect of IFN-β is the basis of its treatment
effect. Particularly, an interference with EBV and MSRV
is suspected. However, the exact mode of its action is
not yet fully understood (for review see [49]). Apart
from EBV and MSRV, IFN-β treatment seems to affect
HHV-6 expression. Patients that fail to suppress HHV-6
during IFN-β treatment have been demonstrated to also
show a poor clinical response [50].
Another line of evidence supporting the pathogenic
role of HHV-6A and EBV in MS comes from the treat-
ment effect of B-cell depletion. Originally, chimeric
monoclonal antibodies against the pan-B cell marker
CD20, in form of rituximab, were used to successfully
treat EBV-related post-transplant lymphoproliferative
disorders (PTLD) [51]. The idea of B-cell depletion with
rituximab was then successfully adopted to treatment of
relapsing-remitting MS [52]. Even better results were
later achieved by using the fully humanized anti-CD20
monoclonal antibody ocrelizumab (OCR) that showed to
be effective not only in relapsing-remitting MS but also
in primary progressive MS [53], illustrating the central
role of B-cells in the pathogenesis of MS.
The third line of evidence comes from treatment with
the α4 integrin (VLA-4) antagonist natalizumab. Treat-
ment with natalizumab carries the risk of provoking
progressive multifocal leukoencephalopathy (PML) caused
by latent JC virus in the CNS (for review see [54]).
However, in addition HHV-6 seems to be reactivated in
the CNS of some natalizumab treated patients [55].
None of the above-mentioned disease-modifying
therapies in MS directly prove the postulated interaction
of HHV-6A and EBV, but all of them are well in line
with infection of both HHV-6A and EBV in the brain of
MS patients.
Conclusion
A link is postulated between HHV-6A and EBV in the
aetio-pathogenesis of MS.
In summary, the tenet is that infection with the neuro-
tropic HHV-6A leads to transformation of latently EBV-
infected B-cells in the CNS. Both viruses will elicit a T-cell
response, either specific towards HHV-6A and EBV, or
non-specific as a response to the HERV-K18-encoded
superantigen. Such viral induced T-cell responses might
secondarily also lead to autoimmune phenomena. Evi-
dence for mechanisms for induction of autoimmunity by
viral infections has recently been reviewed [56].
The hypothesis could be tested on several levels:
 Epidemiological level: The prevalence of genetic
subtypes of EBV (EBNA2) and HHV-6A and its
subtypes are not known. Establishing the prevalence
of co-infection with the two viruses is crucial to
estimate the likelihood of their combined effects
in MS.
 Level of genetic associations to MS: The relations
between MHC2TA as well as EBNA2
polymorphisms with MS suggest a link between
active replication of HHV-6A, regulated by
MHC2TA, and HHV-6A-induced EBNA2
expression in EBV-infected cells. A crucial test
would be to look for genetic interaction between
all three polymorphisms, MHC2TA, EBNA2, and
HERV-K18 in the risk for MS.
 Molecular level: Both, findings for HHV-6A and
EBV expression in MS lesions are not unanimous.
Studies looking for co-expression of the two viruses in
brain tissue of MS patients using the MALDI-TOF
MS technology [57] and/or multiplex detection
of herpes viruses in CSF by PCR [58] might clarify
the issue.
Abbreviations
BRRF2: Tegument protein BRRF2; CMV: Cytomegalo virus; CNS: Central
nervous system; CSF: Cerebrospinal fluid; EBNA2: Epstein Barr Nuclear
Antigen 2; EBV: Epstein Barr Virus; HCV: Hepatitis Virus C; HERV: Human
endogenous retrovirus; HHV-6A: Human Herpes Virus – 6A; HIV: Human
Immunodeficiency Virus; ICSBP, IRF8: Interferon Consensus Sequence-Binding
Protein, Interferon Regulatory Factor 8; IFN-β: Interferon beta; IFN-
γ: Interferon gamma; LMP1: Latent Membrane Protein 1; MALDI-TOF
MS: Matrix Assisted Laser Desorption Ionization — Time of Flight Mass
Spectrometry; MHC2TA, CIITA, Class II: Major Histocompatibility Complex,
Transactivator Gene; MS: Multiple Sclerosis; MSRV: Multiple sclerosis retrovirus;






Availability of data and materials
Not applicable.
Author’s contributions
The author is the corresponding and only author.
Competing interest
The author declares that he has no competing interests.
Consent for publication
Not applicable.
Fierz Virology Journal  (2017) 14:42 Page 3 of 5
Ethics approval and consent to participate
Not applicable.
Received: 9 November 2016 Accepted: 25 February 2017
References
1. Winnock M, Salmon-Céron D, Dabis F, Chêne G. Interaction between HIV-1
and HCV infections: towards a new entity? J Antimicrob Chemother.
2004;53:936–46. doi:10.1093/jac/dkh200.
2. Lin L, Verslype C, van Pelt JF, van Ranst M, Fevery J. Viral interaction and
clinical implications of coinfection of hepatitis C virus with other hepatitis
viruses. Eur J Gastroenterol Hepatol. 2006;18:1311–9. doi:10.1097/01.meg.
0000243881.09820.09.
3. Grivel JC, Ito Y, Fagà G, Santoro F, Shaheen F, Malnati MS, et al. Suppression
of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human
herpesvirus 6. Nat Med. 2001;7:1232–5. doi:10.1038/nm1101-1232.
4. Lisco A, Grivel J-C, Biancotto A, Vanpouille C, Origgi F, Malnati MS, et al. Viral
interactions in human lymphoid tissue: Human herpesvirus 7 suppresses the
replication of CCR5-tropic human immunodeficiency virus type 1 via CD4
modulation. J Virol. 2007;81:708–17. doi:10.1128/JVI.01367-06.
5. Leibovitch EC, Jacobson S. Evidence linking HHV-6 with multiple sclerosis:
an update. Curr Opin Virol. 2014;9:127–33. doi:10.1016/j.coviro.2014.09.016.
6. Pender MP. The essential role of Epstein-Barr virus in the pathogenesis of
multiple sclerosis. Neuroscientist. 2011;17:351–67. doi:10.1177/
1073858410381531.
7. Owens GP, Bennett JL. Trigger, pathogen, or bystander: the complex nexus
linking Epstein- Barr virus and multiple sclerosis. Mult Scler. 2012;18:1204–8.
doi:10.1177/1352458512448109.
8. Fierz W. Virale Hypothese der Multiplen Sklerose. In: Kesselring J, editor.
Multiple Sklerose. 4th ed. Stuttgart: Kohlhammer-Verlag; 2004.
9. Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, et al.
Classification of HHV-6A and HHV-6B as distinct viruses. Arch Virol.
2014;159:863–70. doi:10.1007/s00705-013-1902-5.
10. Donati D, Martinelli E, Cassiani-ingoni R, Ahlqvist J, Hou J, Major EO, et al.
Variant-specific tropism of human herpesvirus 6 in human astrocytes.
J Virol. 2005;79:9439–48. doi:10.1128/JVI.79.15.9439.
11. Alvarez-Lafuente R, Martinez A, Garcia-Montojo M, Mas A, De Las Heras V,
Dominguez-Mozo MI, et al. MHC2TA rs4774C and HHV-6A active replication
in multiple sclerosis patients. Eur J Neurol. 2010;17:129–35.
doi:10.1111/j.1468-1331.2009.02758.x.
12. Bronson PG, Caillier S, Ramsay PP, McCauley JL, Zuvich RL, De Jager PL, et
al. CIITA variation in the presence of HLA-DRB1*1501 increases risk for
multiple sclerosis. Hum Mol Genet. 2010;19:2331–40.
doi:10.1093/hmg/ddq101.
13. Dong Y, Benveniste EN. Immune function of astrocytes. Glia. 2001;36:180–90.
doi:10.1002/glia.1107.
14. Fierz W, Endler B, Reske K, Wekerle H, Fontana A. Astrocytes as antigen-
presenting cells. I. Induction of Ia antigen expression on astrocytes by T
cells via immune interferon and its effect on antigen presentation.
J Immunol. 1985;134:3785–93.
15. Barcia C, Mitxitorena I, Carrillo-de Sauvage MA, Gallego J-M, Pérez-Vallés A.
Imaging the microanatomy of astrocyte-T-cell interactions in immune-
mediated inflammation. Front Cell Neurosci. 2013;7:58. doi:10.3389/fncel.
2013.00058.
16. Meeuwsen S, Persoon-Deen C, Bsibsi M, Bajramovic JJ, Ravid R, De Bolle L,
et al. Modulation of the cytokine network in human adult astrocytes by
human herpesvirus-6A. J Neuroimmunol. 2005;164:37–47.
doi:10.1016/j.jneuroim.2005.03.013.
17. De Jager PL, Jia X, Wang J, de Bakker PIW, Ottoboni L, Aggarwal NT, et al.
Meta-analysis of genome scans and replication identify CD6, IRF8 and
TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet.
2009;41:776–82. doi:10.1038/ng.401.
18. Le Roy E, Mühlethaler-Mottet A, Davrinche C, Mach B, Davignon JL. Escape
of human cytomegalovirus from HLA-DR-restricted CD4(+) T-cell response is
mediated by repression of gamma interferon-induced class II transactivator
expression. J Virol. 1999;73:6582–9.
19. Alenda R, Álvarez-Lafuente R, Costa-Frossard L, Arroyo R, Mirete S, Álvarez-
Cermeño JC, et al. Identification of the major HHV-6 antigen recognized by
cerebrospinal fluid IgG in multiple sclerosis. Eur J Neurol. 2014;21:1096–101.
doi:10.1111/ene.12435.
20. Lossius A, Johansen JN, Vartdal F, Robins H, Benth JŠ, Holmøy T, et al. High-
throughput sequencing of TCR repertoires in multiple sclerosis reveals
intrathecal enrichment of EBV-reactive CD8(+) T cells. Eur J Immunol.
2014;44:3439–52. doi:10.1002/eji.201444662.
21. Van Nierop GP, et al. Intrathecal CD8 T-cells of multiple sclerosis patients
recognize lytic Epstein-Barr virus proteins. Multiple Sclerosis J. 2015.
doi:10.1177/1352458515588581.
22. Petzold A. Intrathecal oligoclonal IgG synthesis in multiple sclerosis.
J Neuroimmunol. 2013;262:1–10. doi:10.1016/j.jneuroim.2013.06.014.
23. Yu X, Burgoon M, Green M, Barmina O, Dennison K, Pointon T, et al.
Intrathecally synthesized IgG in multiple sclerosis cerebrospinal fluid
recognizes identical epitopes over time. J Neuroimmunol.
2011;240–241:129–36.
24. Willis SN, Stathopoulos P, Chastre A, Compton SD, Hafler DA, O’Connor KC.
Investigating the antigen specificity of multiple sclerosis central nervous
system-derived immunoglobulins. Front Immunol. 2015;6:600.
25. Tosato G, Blaese RM, Yarchoan R. Relationship between immunoglobulin
production and immortalization by Epstein Barr virus. J Immunol.
1985;135:959–64.
26. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al.
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain.
J Exp Med. 2007;204:2899–912. doi:10.1084/jem.20071030.
27. Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM. Epstein-Barr virus in the
multiple sclerosis brain: a controversial issue–report on a focused workshop
held in the Centre for Brain Research of the Medical University of Vienna,
Austria. Brain. 2011;134:2772–86. doi:10.1093/brain/awr197.
28. Cepok S, Zhou D, Srivastava R, Nessler S, Stei S, Büssow K, et al.
Identification of Epstein-Barr virus proteins as putative targets of the
immune response in multiple sclerosis. J Clin Invest. 2005;115:1352–60.
doi:10.1172/JCI200523661.1352.
29. Pfuhl C, Oechtering J, Rasche L, Gieß RM, Behrens JR, Wakonig K, et al.
Association of serum Epstein–Barr nuclear antigen-1 antibodies and
intrathecal immunoglobulin synthesis in early multiple sclerosis. J
Neuroimmunol. 2015;285:156–60. doi:10.1016/j.jneuroim.2015.06.012.
30. Flamand L, Stefanescu I, Ablashi DV, Menezes J. Activation of the Epstein-
Barr virus replicative cycle by human herpesvirus 6. J Virol. 1993;67:6768–77.
31. Cuomo L, Angeloni A, Zompetta C, Cirone M, Calogero A, Frati L, et al.
Human herpesvirus 6 variant A, but not variant B, infects EBV-positive B
lymphoid cells, activating the latent EBV genome through a BZLF-1-
dependent mechanism. AIDS Res Hum Retroviruses. 1995;11:1241–5.
doi:10.1089/aid.1995.11.1241.
32. Cuomo L, Trivedi P, De Grazia U, Calogero A, D’Onofrio M, Yang W, et al.
Upregulation of Epstein-Barr virus-encoded latent membrane protein by
human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells.
J Med Virol. 1998;55:219–26. doi:10.1002/(SICI)1096-9071(199807)55:3<219::
AID-JMV7>3.0.CO;2-4.
33. Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, et al.
Epstein-Barr virus genetic variants are associated with multiple sclerosis.
Neurology. 2015;84(13):1362–8. doi:10.1212/WNL.0000000000001420.
34. Juryńczyk M, Selmaj K. Notch: a new player in MS mechanisms.
J Neuroimmunol. 2010;218:3–11. doi:10.1016/j.jneuroim.2009.08.010.
35. Henkel T, Ling PD, Hayward SD, Peterson MG. Mediation of Epstein-Barr
virus EBNA2 transactivation by recombination signal-binding protein
J kappa. Science. 1994;265:92–5. doi:10.1126/science.8016657.
36. Zhao B, Zou J, Wang H, Johannsen E, Peng C-W, Quackenbush J, et al.
Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to
achieve immortal cell growth. Proc Natl Acad Sci U S A. 2011;108:14902–7.
doi:10.1073/pnas.1108892108.
37. Querol L, Clark PL, Bailey MA, Cotsapas C, Cross AH, Hafler DA, et al. Protein
array-based profiling of CSF identifies RBPJ as an autoantigen in multiple
sclerosis. Neurology. 2013;81:956–63. doi:10.1212/WNL.0b013e3182a43b48.
38. Liu H, Zheng H, Li M, Hu D, Tang M, Cao Y. Upregulated expression of
kappa light chain by Epstein-Barr virus encoded latent membrane protein 1
in nasopharyngeal carcinoma cells via NF-kappaB and AP-1 pathways.
Cell Signal. 2007;19:419–27. doi:10.1016/j.cellsig.2006.07.012.
39. Rinker JR, Trinkaus K, Cross AH. Elevated CSF free kappa light chains
correlate with disability prognosis in multiple sclerosis. Neurology.
2006;67:1288–90. doi:10.1212/01.wnl.0000238107.31364.21.
40. Presslauer S, Milosavljevic D, Huebl W, Aboulenein-Djamshidian F, Krugluger
W, Deisenhammer F, et al. Validation of kappa free light chains as a
diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: a
Fierz Virology Journal  (2017) 14:42 Page 4 of 5
multicenter study. Mult Scler J. 2015;online before print:1–9. doi:10.1177/
1352458515594044.
41. Mameli G, Poddighe L, Mei A, Uleri E, Sotgiu S, Serra C, et al. Expression and
activation by Epstein Barr virus of human endogenous retroviruses-W in
blood cells and astrocytes: inference for multiple sclerosis. PLoS One.
2012;7, e44991. doi:10.1371/journal.pone.0044991.
42. Antony JM, Deslauriers AM, Bhat RK, Ellestad KK, Power C. Human
endogenous retroviruses and multiple sclerosis: innocent bystanders or
disease determinants? Biochim Biophys Acta. 1812;2011:162–76.
doi:10.1016/j.bbadis.2010.07.016.
43. Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein-Barr virus
transactivates the human endogenous retrovirus HERV- K18 that encodes a
superantigen. Immunity. 2001;15:579–89.
44. Tai AK, Luka J, Ablashi D, Huber BT. HHV-6A infection induces expression of
HERV-K18-encoded superantigen. J Clin Virol. 2009;46(1):47–8.
doi:10.1016/j.jcv.2009.05.019.
45. Tai AK, O’Reilly EJ, Alroy KA, Simon KC, Munger KL, Huber BT, et al. Human
endogenous retrovirus-K18 Env as a risk factor in multiple sclerosis. Mult
Scler. 2008;14:1175–80. doi:10.1177/1352458508094641.
46. Sutkowski N, Palkama T, Ciurli C, Sekaly RP, Thorley-Lawson DA, Huber BT.
An Epstein-Barr virus-associated superantigen. J Exp Med. 1996;184:971–80.
47. Hong J, et al. A Common TCR V-D-J Sequence in Vβ13.1 T Cells Recognizing
an Immunodominant Peptide of Myelin Basic Protein in Multiple Sclerosis.
J Immunol. 1999;163:3530.
48. Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing-
remitting multiple sclerosis. A randomized, placebo-controlled, double-blind
study. J Neurol. 1996;243:214–24.
49. Annibali V, Mechelli R, Romano S, et al. IFN-β and multiple sclerosis: From
etiology to therapy and back. Cytokine Growth Factor Rev. 2015;26:221–8.
50. Garcia-Montojo M, De Las Heras V, Dominguez-Mozo M, et al. Human
herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis
patients. Eur J Neurol. 2011;18:1027–35. doi:10.1111/j.1468-1331.2011.03410.x.
51. Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal
antibody (Rituximab) treatment for post-transplant lymphoproliferative
disorder. Clin Transplant. 2003;17:417–22.
52. Hauser SL, Waubant E, Arnold DL, et al. B-Cell Depletion with Rituximab in
Relapsing–Remitting Multiple Sclerosis. N Engl J Med. 2008;358:676–88.
doi:10.1056/NEJMoa0706383.
53. Montalban X, Hemmer B, Rammohan K, et al. Efficacy and Safety of
Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase
III Double-Blind, Placebo-Controlled ORATORIO Study (S49.001). Neurology.
2016;86:S49.001.
54. Warnke C, Menge T, Hartung H-P, Racke MK, Cravens PD, Bennett JL, et al.
Natalizumab and progressive multifocal leukoencephalopathy. Arch Neurol.
2010;67:923–30.
55. Yao K, Gagnon S, Akhyani N, Williams E, Fotheringham J, Frohman E, et al.
Reactivation of human herpesvirus-6 in natalizumab treated multiple
sclerosis patients. PLoS One. 2008;3, e2028.
56. Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, et al. Infections
and autoimmunity: the multifaceted relationship. J Leukoc Biol.
2010;87:385–95.
57. Sjöholm MIL, Dillner J, Carlson J. Multiplex detection of human
herpesviruses from archival specimens by using matrix-assisted laser
desorption ionization-time of flight mass spectrometry. J Clin Microbiol.
2008;46:540–5. doi:10.1128/JCM.01565-07.
58. Yamamoto T, Nakamura Y. A single tube PCR assay for simultaneous
amplification of HSV-1/-2, VZV, CMV, HHV-6A/-6B, and EBV DNAs in
cerebrospinal fluid from patients with virus-related neurological diseases.
J Neurovirol. 2000;6:410–7. doi:10.3109/13550280009018305.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Fierz Virology Journal  (2017) 14:42 Page 5 of 5
